A new study from researchers at MSK and Weill Cornell Medicine provides fresh insights about how cancers evolve when they metastasize — insights that could aid in developing strategies to improve the effectiveness of treatment.
Researchers MSK and their collaborators at Mount Sinai have developed an artificial intelligence-based model to predict who will benefit from immune checkpoint inhibitors using only routine blood tests and clinical data.
In a proof-of-concept study, researchers at MSK and the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that uses routine clinical data, such as that from a simple blood test, to predict whether someone’s cancer will respond to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells.
In the Lab
MSK researchers shed light on how the number of mutations in a tumor affect a patient’s response to immunotherapy drugs.
Finding
MSK researchers learn that some cancers may respond to checkpoint inhibitor drugs because of changes called gene fusions.
